Skip to main content

Advancements in First-Line Therapeutics for NSCLC: Navigation of Current Treatment Options for Stage IV Non-Squamous NSCLC

2 of 9 Sessions Available

  • OCT
    02
    October 02, 2019
    Wed 4:00 PM EDT 1H
    Closed
    • The avatar for the contributor named Gary I. Cohen, MD, FACP, FASCO. Gary I. Cohen, MD, FACP, FASCO
  • APR
    23
    April 23, 2020
    Thu 12:30 PM EDT 1H
    Closed
    • The avatar for the contributor named Leora Horn, MD, MSc, FRCPC . Leora Horn, MD, MSc, FRCPC 
  • SEP
    24
    September 24, 2020
    Thu 8:00 AM EDT 1H
    Closed
    • The avatar for the contributor named Gary I. Cohen, MD, FACP, FASCO. Gary I. Cohen, MD, FACP, FASCO
  • OCT
    27
    October 27, 2020
    Tue 12:00 PM MDT 1H
    Closed
  • NOV
    17
    November 17, 2020
    Tue 12:00 PM CST 1H
    Closed
  • NOV
    18
    November 18, 2020
    Wed 7:30 AM CST 1H
    Closed
  • NOV
    23
    November 23, 2020
    Mon 12:00 PM EST 1H
    Closed
  • MAR
    17
    March 17, 2021
    Wed 7:00 PM EDT 1H
    Seats Available
  • APR
    06
    April 06, 2021
    Tue 7:00 AM CDT 1H
    Seats Available

Contributors

  • Gary I. Cohen, MD, FACP, FASCO

    Director Emeritus
    Sandra and Malcolm Berman Cancer Institute Greater
    Baltimore Medical Center
    Associate Professor
    Johns Hopkins Oncology
    Baltimore, MD

    Gary I. Cohen, MD, FACP, FASCO is Director Emeritus, of the Sandra and Malcolm Berman Cancer Institute at Greater Baltimore Medical Center (GBMC). He completed his undergraduate training at Duke University and graduated medical school at the University of Maryland. He subsequently completed his fellowship training in medical oncology at the Dana Farber Cancer Institute of Harvard University. During that time he also completed a fellowship in hematology. He currently holds an appointment as Associate Professor in the Department of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and is board certified in internal medicine, medical oncology and hematology. He is a Fellow of the American Society of Clinical Oncology and Fellow of the American College of Physicians.

    Dr. Cohen established The Cancer Center at GBMC after being appointed Director in 1990. The Center has been listed by US News and World Report as one of the top 50 cancer programs in the US. He has co-authored numerous articles in the medical literature on various aspects of clinical cancer research. Dr. Cohen has been an active participant in the ECOG-ACRIN national cooperative clinical trials group, chairs the Community Scientific Committee, serves as community co-chair of the Melanoma Committee, and sits on the ECOG-ACRIN Executive Council. He is a Founder and Board Member of Gilchrist Hospice Care in Baltimore. He has served on many committees and boards for health-related organizations including the Board of Directors of American Society of Clinical Oncology and Chair of the ASCO Measures Task Force (Quality Care Committee). He served for 20 years as Administrative Director of the Sidney Kimmel Foundation for Cancer Research, which awarded more than $3 million dollars per year to outstanding young cancer scientists. He has won housestaff teaching awards on several occasions and has regularly been listed in local (Baltimore Magazine) and national physician surveys as a "Best Doctor” in Oncology.

  • Leora Horn, MD, MSc, FRCPC 

    Ingram Associate Professor of Cancer Research
    Director, Thoracic Oncology Research Program
    Assistant Vice Chairman for Faculty Development
    Vanderbilt Ingram Cancer Center
    Nashville, TN

    Leora Horn, MD, MSc, FRCPC is an Ingram Associate Professor of Cancer Research at Vanderbilt Ingram Cancer Center and Associate Professor of Medicine in the Division of Hematology/Oncology at the Vanderbilt University Medical Center. Dr. Horn received her Honors Bachelor of Science and Masters of Science in pharmacology from the University of Toronto, where she also attended medical school and trained in internal medicine and medical oncology. She completed a sub-specialty fellowship in thoracic oncology at Vanderbilt University. Her fellowship was funded by an award from the Canadian Association of Medical Oncology.

    Dr. Horn's clinical practice focuses primarily on the care of patients with lung cancer. She is the Clinical Director of the Thoracic Oncology Program at the Vanderbilt-Ingram Cancer Center (VICC). Her research interests include experimental therapeutics and medical education. Her work has been recognized with a VICC Impact Award annually for the last eight years for her research contributions.

    Dr. Horn is currently completing a Masters in Health Professional Education through the University of Illinois Chicago and is the Assistant Vice Chairman for Faculty Development in the Department of Medicine, where she runs the Schaffner Society to support the careers of clinician educators in the Department of Medicine.

    Dr. Horn is Principal Investigator on several lung cancer clinical trials and educational projects. She has published more than 100 papers and book chapters including original papers, reviews, and the recent chapter on "neoplasms of the lung" in Harrison's Principles of Internal Medicine, 20th edition. She is an active member in the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.

  • Mitra Mehrad, MD 

    Assistant Professor
    Associate Director, Surgical Pathology Fellowship
    Pathology, Microbiology and Immunology
    Vanderbilt University Medical Center
    Nashville, TN

    Mitra Mehrad, MD is an Assistant Professor of Pathology at Vanderbilt University Medical Center with a subspecialty focus in thoracic pathology. Her diagnostic expertise include neoplastic and non-neoplastic diseases of the lung and mediastinum, as well as lung transplantation. Dr. Mehrad’s research interests include the pathology of interstitial lung disease and molecular profiling of lung cancer to identify biomarkers that may have diagnostic, prognostic, and treatment implications. She is an active member of the Pulmonary Pathology Society and the American Society for Clinical Pathology Lung Cancer DxToolkit steering committee.

2 of 9 Sessions Available